Skip to search formSkip to main contentSkip to account menu

TAC 101

Known as: TAC-101 
A retinobenzoic acid with potential antineoplastic activity. TAC-101 inhibits retinoblastoma-gene product (RB) phosphorylation and increases the… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
PurposePreclinical models showed TAC-101 (4-[3,5-bis(trimethylsilyl) benzamide] benzoic acid), an oral synthetic retinoid, has… 
2005
2005
BACKGROUND 4-[3,5-Bis (trimethylsilyl) benzamido] benzoic acid (TAC-101) is a novel retinobenzoic acid derivative, which has a… 
2003
2003
Purpose: Retinoid analogues have been reported to inhibit the growth of hepatocellular carcinoma (HCC). However, the expression… 
2002
2002
The effect of 4-[3,5-bis(trimethylsilyl)benzamido] benzoic acid (TAC-101), one of the synthetic retinoids, on collagen-induced… 
2001
2001
TAC‐101 (4‐[3,5‐bis(trimethylsilyl)benzamido]benzoic acid) is a novel, synthetic retinoid that is effective against liver… 
2000
2000
We examined the effects of TAC-101 on the invasion and metastasis of human non-small cell lung cancer (NSCLC) cell lines. TAC-101… 
2000
2000
BACKGROUND The incidence of cancers of the digestive tract has been high among all of the cancers in Japan and the western… 
1999
1999
The anti‐tumor and anti‐metastatic effects of 4‐[3,5‐bis(trimethylsilyl)benzamido]benzoic acid (TAC‐101) were investigated using… 
1998
1998
We examined the in vivo anti-tumor activity of the benzoic acid derivative, TAC-101 (4-[3,5- bis(trimethylsilyl)benzamido…